Skip to Main Content

Author Details

Qian Shi
117902Beijing TongRen Hospital, Capital Medical University
2004
156
46
PMIDPaper TitleJournal TitlePublished Year
35938483Prognostic Analysis of Individualized Treatments of Malignant Tumors Primary From Maxillary Sinus.Ear Nose Throat J2024
37639322Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma.Blood Adv2024
34225302Chemoradiation and Local Excision Versus Total Mesorectal Excision for T2N0 Rectal Cancer: Comparison of Short- and Long-Term Outcomes From 2 Prospective Studies.Ann Surg2023
37627145Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.Cancers (Basel)2023
37619846Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.Ann Oncol2023
37507606A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative.Nat Med2023
37651160Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).Cancer2023
37289007Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).Clin Cancer Res2023
37179438Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance).Br J Cancer2023
37270691Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).J Clin Oncol2023
37334719Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).Ann Surg2023
36547945Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.JAMA Oncol2023
36878665Association between physical activity and the time course of cancer recurrence in stage III colon cancer.Br J Sports Med2023
36701146Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer.JAMA Oncol2023
36367997Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.J Clin Oncol2023
36306483Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.J Clin Oncol2023
35944235Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).J Clin Oncol2023
34505880Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.J Natl Cancer Inst2022
35772047Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.JCO Precis Oncol2022
35671005Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.Clin Cancer Res2022
35642291Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials.Stat Methods Med Res2022
35603849Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.JNCI Cancer Spectr2022
35491747End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.Br J Haematol2022
36045021Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.Clin Lymphoma Myeloma Leuk2022
35970919Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.Nat Med2022
35994794Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.Eur J Cancer2022
36267789Challenges, opportunities, and innovative statistical designs for precision oncology trials.Ann Transl Med2022
35984985Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.Cancer Epidemiol Biomarkers Prev2022
36006624Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.JAMA Oncol2022
35279470Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.Eur J Cancer2022
35005992Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.JCO Precis Oncol2022
35033994Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ⿥ 70 years.Eur J Cancer2022
34614146Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.Blood2022
32778736International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Leukemia2021
33821899Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.JAMA2021
33734401BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.J Natl Cancer Inst2021
33775561Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.Clin Colorectal Cancer2021
33749762Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.Blood Adv2021
33661547Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.Am J Hematol2021
33772843Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).Stat Med2021
35003378A Statistical Method for Association Analysis of Cell Type Compositions.Stat Biosci2021
34405233Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.J Natl Cancer Inst2021
34752136Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.J Clin Oncol2021
34485815Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.JNCI Cancer Spectr2021
33934058Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).Eur J Cancer2021
34061178Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.J Natl Cancer Inst2021
33972368Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study.Cancer Epidemiol Biomarkers Prev2021
33341444Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.Eur J Cancer2021
33160272Modeling cancer clinical trials using HL7 FHIR to support downstream applications: A case study with colorectal cancer data.Int J Med Inform2021
33356421Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.J Clin Oncol2021
  • 1 - 50 of 156

Recommended Authors

Chen Hu
Johns Hopkins University School of Medicine
Career Start Year 2009
Number of shared co-authors 2
Stephen Welch
Victoria Hospital
Career Start Year 2007
Number of shared co-authors 1
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 0
Emmanouil Fokas
Universityhospital Frankfurt
Career Start Year 2007
Number of shared co-authors 2
Sunita Ghosh
Cross Cancer Institute
Career Start Year 2006
Number of shared co-authors 0
Liz-Anne Lewsley
CRUK Clinical Trials Unit, University of Glasgow
Career Start Year 2006
Number of shared co-authors 3
Celina Ang
Tisch Cancer Institute, Mount Sinai Hospital
Career Start Year 2005
Number of shared co-authors 1
Kouros Owzar
Duke University
Career Start Year 2005
Number of shared co-authors 5
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 2
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 1
Nora Horick
Massachusetts General Hospital
Career Start Year 2003
Number of shared co-authors 1
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 2
Lissandra Dal Lago
Institut Jules Bordet
Career Start Year 2002
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 7
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 3
Hanneke W M van Laarhoven
Cancer Center Amsterdam
Career Start Year 2001
Number of shared co-authors 3
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 2
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 1
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 1
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year 1997
Number of shared co-authors 2
Joon Oh Park
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 1
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 7
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Career Start Year 1995
Number of shared co-authors 3
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 4
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 1
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Career Start Year 1992
Number of shared co-authors 9
Wei Xu
Princess Margaret Cancer Centre
Career Start Year 1991
Number of shared co-authors 1
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 7
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 3

Collaborators

Steven R Alberts
Mayo Clinic
Co-authored papers 37
Thomas J George
UF Health Cancer Center
Co-authored papers 9
Robert B Diasio
Mayo Clinic
Co-authored papers 8
Michael J O'Connell
NSABP Foundation
Co-authored papers 8
Fang-Shu Ou
Mayo Clinic
Co-authored papers 7
Suresh Nair
Lehigh Valley Topper Cancer Institute
Co-authored papers 7
Andrew T Chan
Massachusetts General Hospital and Harvard Medical School
Co-authored papers 6
Pierre Laurent-Puig
Co-authored papers 5
Ulrike Peters
Co-authored papers 5
Stephen N Thibodeau
Mayo Clinic
Co-authored papers 5
Brian M Bot
Co-authored papers 5
Deborah Schrag
Memorial-Sloan Kettering Cancer Center
Co-authored papers 4
Wei Sun
Co-authored papers 3
Erin M Green
University of Maryland Baltimore County
Co-authored papers 3
Mohammad Hassan Murad
Evidence Foundation
Co-authored papers 3
Yves Fradet
CHU de Quebec-Universite Laval
Co-authored papers 3
Al B Benson
Northwestern University Feinberg School of Medicine
Co-authored papers 3
Victor M Montori
Knowledge and Evaluation Research Unit in Endocrinology (KER_Endo), Mayo Clinic
Co-authored papers 3
Andrew Wen
Mayo Clinic
Co-authored papers 2
Chen Wang
Center for Individualized Medicine, Mayo Clinic
Co-authored papers 2
Priya Kumthekar
Northwestern University, Feinberg School of Medicine
Co-authored papers 2
Jeffrey B Geske
Mayo Clinic
Co-authored papers 2
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 2
Yue Yu
Health Sciences Mayo Clinic
Co-authored papers 2
Nansu Zong
Mayo Clinic
Co-authored papers 2
Navtej S Buttar
Mayo Clinic
Co-authored papers 2
Steven A Smith
Mayo Clinic
Co-authored papers 2
Kathryn L Penney
Co-authored papers 2
Guoqian Jiang
Mayo Clinic Rochester Minnesota USA.
Co-authored papers 2
Rickey E Carter
Mayo Clinic
Co-authored papers 2
Release 1.2